Chronic obstructive pulmonary disease (COPD), the fourth leading cause of mortality worldwide, is characterized by persistent and progressive airflow limitation, due to chronic inflammatory response in airways and lungs. In the past decade, some new non-corticosteroid drugs were applied to alleviate the inflammation in COPD, but few achieved the ideal outcomes.
